1. (1995) Polycythemia vera: the natural history of 1213 patients followed for 20 years. Gruppo Italiano Studio Policitemia. *Annals of internal medicine* **123**, 656-664.

2. Abdulkarim K, Girodon F, Johansson P *et al.* (2009) AML transformation in 56 patients with Ph- MPD in two well defined populations. *Eur J Haematol* **82**, 106-111.

3. Ades L, Itzykson R, Fenaux P (2014) Myelodysplastic syndromes. *Lancet* **383**, 2239-2252.

4. Allemani C, Weir HK, Carreira H *et al.* (2015) Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). *Lancet* **385**, 977-1010.

5. Altekruse SF, Henley SJ, Thun MJ (1999) Deaths from hematopoietic and other cancers in relation to permanent hair dye use in a large prospective study (United States). *Cancer Causes Control* **10**, 617-625.

6. Anderson LA, Duncombe AS, Hughes M *et al.* (2012) Environmental, lifestyle, and familial/ethnic factors associated with myeloproliferative neoplasms. *Am J Hematol* **87**, 175-182.

7. Anderson LA, Pfeiffer RM, Landgren O *et al.* (2009) Risks of myeloid malignancies in patients with autoimmune conditions. *Br J Cancer* **100**, 822-828.

8. Bachand AM, Mundt KA, Mundt DJ *et al.* (2010) Epidemiological studies of formaldehyde exposure and risk of leukemia and nasopharyngeal cancer: a meta-analysis. *Crit Rev Toxicol* **40**, 85-100.

9. Band PR, Le ND, Fang R *et al.* (1996) Cohort study of Air Canada pilots: mortality, cancer incidence, and leukemia risk. *Am J Epidemiol* **143**, 137-143.

10. Barbui T (2004) The leukemia controversy in myeloproliferative disorders: is it a natural progression of disease, a secondary sequela of therapy, or a combination of both? *Semin Hematol* **41**, 15-17.

11. Barbui T, Thiele J, Passamonti F *et al.* (2011) Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. *J Clin Oncol* **29**, 3179-3184.

12. Beane Freeman LE, Blair A, Lubin JH *et al.* (2009) Mortality from lymphohematopoietic malignancies among workers in formaldehyde industries: the National Cancer Institute Cohort. *J Natl Cancer Inst* **101**, 751-761.

13. Beane Freeman LE, Bonner MR, Blair A *et al.* (2005) Cancer incidence among male pesticide applicators in the Agricultural Health Study cohort exposed to diazinon. *Am J Epidemiol* **162**, 1070-1079.

14. Bennett JM (2013) The myelodysplastic syndromes: a personal recollection of four decades of classification and prognostic scoring systems. *Leuk Lymphoma* **54**, 2588-2591.

15. Bennett JM, Catovsky D, Daniel MT *et al.* (1994) The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukaemia Group. *British journal of haematology* **87**, 746-754.

16. Bennett JM, Catovsky D, Daniel MT *et al.* (1989) Proposals for the classification of chronic (mature) B and T lymphoid leukaemias. French-American-British (FAB) Cooperative Group. *J Clin Pathol* **42**, 567-584.

17. Bhatia S (2013) Therapy-related myelodysplasia and acute myeloid leukemia. *Semin Oncol* **40**, 666-675.

18. Bjork J, Albin M, Welinder H *et al.* (2001) Are occupational, hobby, or lifestyle exposures associated with Philadelphia chromosome positive chronic myeloid leukaemia? *Occup Environ Med* **58**, 722-727.

19. Bjorkholm M, Derolf AR, Hultcrantz M *et al.* (2011) Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms. *J Clin Oncol* **29**, 2410-2415.

20. Blackwelder WC, Yano K, Rhoads GG *et al.* (1980) Alcohol and mortality: the Honolulu Heart Study. *Am J Med* **68**, 164-169.

21. Blair A, Zahm SH (1995) Agricultural exposures and cancer. *Environ Health Perspect* **103 Suppl 8**, 205-208.

22. Bochicchio F, Hulka J, Ringer W *et al.* (2014) National radon programmes and policies: the RADPAR recommendations. *Radiat Prot Dosimetry* **160**, 14-17.

23. Bochtler T, Frohling S, Kramer A (2015) Role of chromosomal aberrations in clonal diversity and progression of acute myeloid leukemia. *Leukemia* **29**, 1243-1252.

24. Boice JD, Jr. (2006) Ionizing radiation. In *Cancer Epidemiology and Prevention*, 3rd ed., pp. 259-293 [D Schottenfeld and JF Fraumeni, editors]. New York: Oxford University.

25. Boice JD, Jr., Blettner M, Kleinerman RA *et al.* (1987) Radiation dose and leukemia risk in patients treated for cancer of the cervix. *J Natl Cancer Inst* **79**, 1295-1311.

26. Boice JD, Jr., Morin MM, Glass AG *et al.* (1991) Diagnostic x-ray procedures and risk of leukemia, lymphoma, and multiple myeloma. *JAMA* **265**, 1290-1294.

27. Brown LM, Gibson R, Burmeister LF *et al.* (1992) Alcohol consumption and risk of leukemia, non-Hodgkin's lymphoma, and multiple myeloma. *Leuk Res* **16**, 979-984.

28. Caldwell GG, Kelley DB, Heath CW, Jr. (1980) Leukemia among participants in military maneuvers at a nuclear bomb test. A preliminary report. *JAMA* **244**, 1575-1578.

29. Campbell PJ, Green AR (2006) The myeloproliferative disorders. *N Engl J Med* **355**, 2452-2466.

30. Candelaria M, Duenas-Gonzalez A (2015) Therapy-related myelodysplastic syndrome. *Expert Opin Drug Saf* **14**, 655-665.

31. Cantor KP, Blair A, Everett G *et al.* (1988) Hair dye use and risk of leukemia and lymphoma. *Am J Public Health* **78**, 570-571.

32. Cardis E, Vrijheid M, Blettner M *et al.* (2005) Risk of cancer after low doses of ionising radiation: retrospective cohort study in 15 countries. *BMJ* **331**, 77.

33. Carstensen JM, Bygren LO, Hatschek T (1990) Cancer incidence among Swedish brewery workers. *Int J Cancer* **45**, 393-396.

34. Cartwright RA, Darwin C, McKinney PA *et al.* (1988) Acute myeloid leukemia in adults: a case-control study in Yorkshire. *Leukemia* **2**, 687-690.

35. Castillo JJ, Reagan JL, Ingham RR *et al.* (2012) Obesity but not overweight increases the incidence and mortality of leukemia in adults: a meta-analysis of prospective cohort studies. *Leuk Res* **36**, 868-875.

36. Chen J, Odenike O, Rowley JD (2010) Leukaemogenesis: more than mutant genes. *Nat Rev Cancer* **10**, 23-36.

37. Cogle CR (2015) Incidence and Burden of the Myelodysplastic Syndromes. *Current hematologic malignancy reports* **10**, 272-281.

38. Cohen T, Creger WP (1967) Acute myeloid leukemia following seven years of aplastic anemia induced by chloramphenicol. *Am J Med* **43**, 762-770.

39. Cooper GS, Kamel F, Sandler DP *et al.* (1996) Risk of adult acute leukemia in relation to prior immune-related conditions. *Cancer Epidemiol Biomarkers Prev* **5**, 867-872.

40. Correa A, Mohan A, Jackson L *et al.* (2000) Use of hair dyes, hematopoietic neoplasms, and lymphomas: a literature review. I. Leukemias and myelodysplastic syndromes. *Cancer Invest* **18**, 366-380.

41. Council NR (2006) *Health Risks from Exposure to Low Levels of Ionizing Radiation: BEIR VII Phase 2.* Washington, DC: The National Academies Press.

42. Cowell IG, Sondka Z, Smith K *et al.* (2012) Model for MLL translocations in therapy-related leukemia involving topoisomerase IIbeta-mediated DNA strand breaks and gene proximity. *Proc Natl Acad Sci U S A* **109**, 8989-8994.

43. Craig BM, Rollison DE, List AF *et al.* (2012) Underreporting of myeloid malignancies by United States cancer registries. *Cancer Epidemiol Biomarkers Prev* **21**, 474-481.

44. Dameshek W (1951) Some speculations on the myeloproliferative syndromes. *Blood* **6**, 372-375.

45. Daniels RD, Schubauer-Berigan MK (2011) A meta-analysis of leukaemia risk from protracted exposure to low-dose gamma radiation. *Occup Environ Med* **68**, 457-464.

46. Darby SC, Whitley E, Howe GR *et al.* (1995) Radon and cancers other than lung cancer in underground miners: a collaborative analysis of 11 studies. *J Natl Cancer Inst* **87**, 378-384.

47. Dohner H, Weisdorf DJ, Bloomfield CD (2015) Acute Myeloid Leukemia. *N Engl J Med* **373**, 1136-1152.

48. Doody MM, Linet MS, Glass AG *et al.* (1996) Risks of non-Hodgkin's lymphoma, multiple myeloma, and leukemia associated with common medications. *Epidemiology* **7**, 131-139.

49. Doody MM, Linet MS, Glass AG *et al.* (1992) Leukemia, lymphoma, and multiple myeloma following selected medical conditions. *Cancer Causes Control* **3**, 449-456.

50. Dores GM, Devesa SS, Curtis RE *et al.* (2012) Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007. *Blood* **119**, 34-43.

51. Du Y, Fryzek J, Sekeres MA *et al.* (2010) Smoking and alcohol intake as risk factors for myelodysplastic syndromes (MDS). *Leuk Res* **34**, 1-5.

52. Elliott P, Shaddick G, Douglass M *et al.* (2013) Adult cancers near high-voltage overhead power lines. *Epidemiology* **24**, 184-190.

53. Evans DG, Birch JM, Ramsden RT *et al.* (2006) Malignant transformation and new primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour prone syndromes. *J Med Genet* **43**, 289-294.

54. Ferlay J, Soerjomataram I, Ervik M *et al.* (2014) Cancer Incidence and Mortality Worldwide. http://www.wcrf.org/int/cancer-facts-figures/worldwide-data

55. Fernberg P, Odenbro A, Bellocco R *et al.* (2007) Tobacco use, body mass index, and the risk of leukemia and multiple myeloma: a nationwide cohort study in Sweden. *Cancer Res* **67**, 5983-5986.

56. Ferrara F, Schiffer CA (2013) Acute myeloid leukaemia in adults. *Lancet* **381**, 484-495.

57. Feychting M, Ahlbom A (1994) Magnetic fields, leukemia, and central nervous system tumors in Swedish adults residing near high-voltage power lines. *Epidemiology* **5**, 501-509.

58. Fircanis S, Merriam P, Khan N *et al.* (2014) The relation between cigarette smoking and risk of acute myeloid leukemia: an updated meta-analysis of epidemiological studies. *Am J Hematol* **89**, E125-132.

59. Fleenor CJ, Higa K, Weil MM *et al.* (2015) Evolved Cellular Mechanisms to Respond to Genotoxic Insults: Implications for Radiation-Induced Hematologic Malignancies. *Radiat Res* **184**, 341-351.

60. Fraumeni JF, Jr. (1967) Bone marrow depression induced by chloramphenicol or phenylbutazone. Leukemia and other sequelae. *JAMA* **201**, 828-834.

61. Friedman GD (1982) Phenylbutazone, musculoskeletal disease, and leukemia. *J Chronic Dis* **35**, 233-243.

62. Fritz A, Percy C, Jack A *et al.* (editors) (2000) *International Classification of Diseases for Oncology*, 3rd ed*.* Geneva, Switzerland: World Health Organization.

63. Gangatharan SA, Grove CS, P'ng S *et al.* (2013) Acute myeloid leukaemia in Western Australia 1991-2005: a retrospective population-based study of 898 patients regarding epidemiology, cytogenetics, treatment and outcome. *Internal medicine journal* **43**, 903-911.

64. Giagounidis A, Haase D (2013) Morphology, cytogenetics and classification of MDS. *Best practice & research* **26**, 337-353.

65. Glass DC, Schnatter AR, Tang G *et al.* (2014) Risk of myeloproliferative disease and chronic myeloid leukaemia following exposure to low-level benzene in a nested case-control study of petroleum workers. *Occup Environ Med* **71**, 266-274.

66. Gluzman DF, Sklyarenko LM, Koval SV *et al.* (2015) Myelodysplastic syndromes in Chernobyl clean-up workers. *Ann Hematol* **94**, 1639-1643.

67. Godley LA, Larson RA (2008) Therapy-related myeloid leukemia. *Semin Oncol* **35**, 418-429.

68. Goldberg SL, Chen E, Corral M *et al.* (2010) Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. *J Clin Oncol* **28**, 2847-2852.

69. Greenberg P, Cox C, LeBeau MM *et al.* (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. *Blood* **89**, 2079-2088.

70. Greenberg PL, Tuechler H, Schanz J *et al.* (2012) Revised international prognostic scoring system for myelodysplastic syndromes. *Blood* **120**, 2454-2465.

71. Griem ML, Kleinerman RA, Boice JD, Jr. *et al.* (1994) Cancer following radiotherapy for peptic ulcer. *J Natl Cancer Inst* **86**, 842-849.

72. Grimwade D (2001) The clinical significance of cytogenetic abnormalities in acute myeloid leukaemia. *Best practice & research* **14**, 497-529.

73. Grimwade D, Hills RK, Moorman AV *et al.* (2010) Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. *Blood* **116**, 354-365.

74. Groves FD, Page WF, Gridley G *et al.* (2002) Cancer in Korean war navy technicians: mortality survey after 40 years. *Am J Epidemiol* **155**, 810-818.

75. Gundestrup M, Storm HH (1999) Radiation-induced acute myeloid leukaemia and other cancers in commercial jet cockpit crew: a population-based cohort study. *Lancet* **354**, 2029-2031.

76. Hammer GP, Auvinen A, De Stavola BL *et al.* (2014) Mortality from cancer and other causes in commercial airline crews: a joint analysis of cohorts from 10 countries. *Occup Environ Med* **71**, 313-322.

77. Harada H, Harada Y, Tanaka H *et al.* (2003) Implications of somatic mutations in the AML1 gene in radiation-associated and therapy-related myelodysplastic syndrome/acute myeloid leukemia. *Blood* **101**, 673-680.

78. Harrison J (2009) Biokinetic and dosimetric modelling in the estimation of radiation risks from internal emitters. *J Radiol Prot* **29**, A81-A105.

79. Hauptmann M, Lubin JH, Stewart PA *et al.* (2003) Mortality from lymphohematopoietic malignancies among workers in formaldehyde industries. *J Natl Cancer Inst* **95**, 1615-1623.

80. Hauptmann M, Stewart PA, Lubin JH *et al.* (2009) Mortality from lymphohematopoietic malignancies and brain cancer among embalmers exposed to formaldehyde. *J Natl Cancer Inst* **101**, 1696-1708.

81. Hayes RB, Yin SN, Dosemeci M *et al.* (1997) Benzene and the dose-related incidence of hematologic neoplasms in China. Chinese Academy of Preventive Medicine--National Cancer Institute Benzene Study Group. *J Natl Cancer Inst* **89**, 1065-1071.

82. Hemminki K, Liu X, Forsti A *et al.* (2013) Subsequent leukaemia in autoimmune disease patients. *British journal of haematology* **161**, 677-687.

83. Henshaw DL, Eatough JP, Richardson RB (1990) Radon as a causative factor in induction of myeloid leukaemia and other cancers. *Lancet* **335**, 1008-1012.

84. Hinds MW, Kolonel LN, Lee J *et al.* (1980) Associations between cancer incidence and alcohol/cigarette consumption among five ethnic groups in Hawaii. *Br J Cancer* **41**, 929-940.

85. Howard R, Gilbert E, Lynch CF *et al.* (2008) Risk of leukemia among survivors of testicular cancer: a population-based study of 42,722 patients. *Ann Epidemiol* **18**, 416-421.

86. Hsu WL, Preston DL, Soda M *et al.* (2013) The incidence of leukemia, lymphoma and multiple myeloma among atomic bomb survivors: 1950-2001. *Radiat Res* **179**, 361-382.

87. IARC (2001) Ionizing radiation, part 2: some internally deposited radionuclides. *IARC Monogr Eval Carcinog Risks Hum* **78**, 595.

88. IARC (2010) Some aromatic amines, organic dyes, and related exposures. *IARC Monogr Eval Carcinog Risks Hum* **99**, 692.

89. IARC (2012) Chemical agents and related occupations. *IARC Monogr Eval Carcinog Risks Hum* **100(Pt F)**, 599.

90. IARC (2013) Non-ionizing radiation, part 2: radiofrequency electromagnetic fields. *IARC Monogr Eval Carcinog Risks Hum* **102**, 460.

91. Ido M, Nagata C, Kawakami N *et al.* (1996) A case-control study of myelodysplastic syndromes among Japanese men and women. *Leuk Res* **20**, 727-731.

92. Inaba H, Greaves M, Mullighan CG (2013) Acute lymphoblastic leukaemia. *Lancet* **381**, 1943-1955.

93. Iwanaga M, Hsu WL, Soda M *et al.* (2011) Risk of myelodysplastic syndromes in people exposed to ionizing radiation: a retrospective cohort study of Nagasaki atomic bomb survivors. *J Clin Oncol* **29**, 428-434.

94. Jablon S, Hrubec Z, Boice JD, Jr. (1991) Cancer in populations living near nuclear facilities. A survey of mortality nationwide and incidence in two states. *JAMA* **265**, 1403-1408.

95. Jaffe ES, Harris NL, Stein H *et al.* (editors) (2001) *World Health Organization classification of tumours. Pathology and genetics of haematopoietic and lymphoid tissues.* Lyon: IARC Press.

96. James C, Ugo V, Le Couedic JP *et al.* (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. *Nature* **434**, 1144-1148.

97. Johansen C, Raaschou Nielsen O, Olsen JH *et al.* (2007) Risk for leukaemia and brain and breast cancer among Danish utility workers: a second follow-up. *Occup Environ Med* **64**, 782-784.

98. Kabat GC, Wu JW, Moore SC *et al.* (2013) Lifestyle and dietary factors in relation to risk of chronic myeloid leukemia in the NIH-AARP Diet and Health Study. *Cancer Epidemiol Biomarkers Prev* **22**, 848-854.

99. Kadia TM, Ravandi F, Cortes J *et al.* (2015) Toward Individualized Therapy in Acute Myeloid Leukemia: A Contemporary Review. *JAMA oncology* **1**, 820-828.

100. Karran P (2006) Thiopurines, DNA damage, DNA repair and therapy-related cancer. *Br Med Bull* **79-80**, 153-170.

101. Kaye FJ (2009) Mutation-associated fusion cancer genes in solid tumors. *Mol Cancer Ther* **8**, 1399-1408.

102. Kendall G, Muirhead C (2003) Third epidemiological study of participants in the UK atmospheric nuclear weapons tests. *J Radiol Prot* **23**, 213-214.

103. Khalade A, Jaakkola MS, Pukkala E *et al.* (2010) Exposure to benzene at work and the risk of leukemia: a systematic review and meta-analysis. *Environ Health* **9**, 31.

104. Kheifets L, Monroe J, Vergara X *et al.* (2008) Occupational electromagnetic fields and leukemia and brain cancer: an update to two meta-analyses. *J Occup Environ Med* **50**, 677-688.

105. Kheifets LI, Afifi AA, Buffler PA *et al.* (1997) Occupational electric and magnetic field exposure and leukemia. A meta-analysis. *J Occup Environ Med* **39**, 1074-1091.

106. Kinlen LJ, Rogot E (1988) Leukaemia and smoking habits among United States veterans. *BMJ* **297**, 657-659.

107. Kipps TJ, Huan-You W Classification of malignant lymphoid disorders In *Williams Hematatology*, 8th ed.

108. Koeman T, van den Brandt PA, Slottje P *et al.* (2014) Occupational extremely low-frequency magnetic field exposure and selected cancer outcomes in a prospective Dutch cohort. *Cancer Causes Control* **25**, 203-214.

109. Kralovics R, Passamonti F, Buser AS *et al.* (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. *N Engl J Med* **352**, 1779-1790.

110. Krestinina L, Preston DL, Davis FG *et al.* (2010) Leukemia incidence among people exposed to chronic radiation from the contaminated Techa River, 1953-2005. *Radiat Environ Biophys* **49**, 195-201.

111. Kristinsson SY, Bjorkholm M, Hultcrantz M *et al.* (2011) Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes. *J Clin Oncol* **29**, 2897-2903.

112. Kroll ME, Murphy F, Pirie K *et al.* (2012) Alcohol drinking, tobacco smoking and subtypes of haematological malignancy in the UK Million Women Study. *Br J Cancer* **107**, 879-887.

113. Lan Q, Zhang L, Li G *et al.* (2004) Hematotoxicity in workers exposed to low levels of benzene. *Science* **306**, 1774-1776.

114. Laurier D, Jacob S, Bernier MO *et al.* (2008) Epidemiological studies of leukaemia in children and young adults around nuclear facilities: a critical review. *Radiat Prot Dosimetry* **132**, 182-190.

115. Laurier D, Valenty M, Tirmarche M (2001) Radon exposure and the risk of leukemia: a review of epidemiological studies. *Health Phys* **81**, 272-288.

116. Leal AD, Thompson CA, Wang AH *et al.* (2014) Anthropometric, medical history and lifestyle risk factors for myeloproliferative neoplasms in the Iowa Women's Health Study cohort. *Int J Cancer* **134**, 1741-1750.

117. Lee WJ, Hoppin JA, Blair A *et al.* (2004) Cancer incidence among pesticide applicators exposed to alachlor in the Agricultural Health Study. *Am J Epidemiol* **159**, 373-380.

118. Lehmann S, Ravn A, Carlsson L *et al.* (2011) Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry. *Leukemia* **25**, 1128-1134.

119. Leone G, Fianchi L, Pagano L *et al.* (2010) Incidence and susceptibility to therapy-related myeloid neoplasms. *Chem Biol Interact* **184**, 39-45.

120. Leuraud K, Richardson DB, Cardis E *et al.* (2015) Ionising radiation and risk of death from leukaemia and lymphoma in radiation-monitored workers (INWORKS): an international cohort study. *Lancet Haematol* **2**, e276-e281.

121. Li Y, Moysich KB, Baer MR *et al.* (2006) Intakes of selected food groups and beverages and adult acute myeloid leukemia. *Leuk Res* **30**, 1507-1515.

122. Lichtman MA Classification and clinical manifestations of the clonal myeloid disorders. In *Willliams Hematology*, 8th ed.

123. Linet MS, Cartwright RA (1988) Chronic lymphocytic leukemia: epidemiology and etiologic findings. *Nouv Rev Fr Hematol* **30**, 353-357.

124. Linet MS, Devesa SS, Morgan GJ (2006) The Leukemias. In *Cancer Epidemiology and Prevention*, 3rd ed., pp. 841-871 [D Schottenfeld and JF Fraumeni, editors]. New York: Oxford University Press.

125. Linet MS, Kim KP, Miller DL *et al.* (2010) Historical review of occupational exposures and cancer risks in medical radiation workers. *Radiat Res* **174**, 793-808.

126. Linet MS, Schubauer-Berigan MK, Weisenburger DD *et al.* (2007) Chronic lymphocytic leukaemia: an overview of aetiology in light of recent developments in classification and pathogenesis. *British journal of haematology* **139**, 672-686.

127. Linet MS, Slovis TL, Miller DL *et al.* (2012) Cancer risks associated with external radiation from diagnostic imaging procedures. *CA Cancer J Clin* **62**, 75-100.

128. Linet MS, Yin SN, Gilbert ES *et al.* (2015) A retrospective cohort study of cause-specific mortality and incidence of hematopoietic malignancies in Chinese benzene-exposed workers. *Int J Cancer* **137**, 2184-2197.

129. Liu P, Holman CD, Jin J *et al.* (2015) Dietary isoflavone intake is associated with a reduced risk of myelodysplastic syndromes. *Br J Nutr* **114**, 2110-2115.

130. Liu P, Holman CD, Jin J *et al.* (2016) Alcohol consumption and risk of myelodysplastic syndromes: a case-control study. *Cancer Causes Control* **27**, 209-216.

131. Lundberg P, Karow A, Nienhold R *et al.* (2014) Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. *Blood* **123**, 2220-2228.

132. Ma X, Lim U, Park Y *et al.* (2009) Obesity, lifestyle factors, and risk of myelodysplastic syndromes in a large US cohort. *Am J Epidemiol* **169**, 1492-1499.

133. Ma X, Park Y, Mayne ST *et al.* (2010) Diet, lifestyle, and acute myeloid leukemia in the NIH-AARP cohort. *Am J Epidemiol* **171**, 312-322.

134. Mabuchi K, Fugiwara S, Preston DL *et al.* (2011) Atomic bomb survivors: long-term health effects of radiation. In *Human Radiation Injury* [DS Shrieve and JS Loeffler, editors]. Philadelphia: Wolters Kuwer/Lippincott Williams and Wilkins.

135. Mahajan R, Blair A, Lynch CF *et al.* (2006) Fonofos exposure and cancer incidence in the agricultural health study. *Environ Health Perspect* **114**, 1838-1842.

136. March HC (1950) Leukemia in radiologists in a 20 year period. *Am J Med Sci* **220**, 282-286.

137. Matsuo T, Tomonaga M, Bennett JM *et al.* (1988) Reclassification of leukemia among A-bomb survivors in Nagasaki using French-American-British (FAB) classification for acute leukemia. *Jpn J Clin Oncol* **18**, 91-96.

138. Maynadie M, Girodon F, Manivet-Janoray I *et al.* (2011) Twenty-five years of epidemiological recording on myeloid malignancies: data from the specialized registry of hematologic malignancies of Cote d'Or (Burgundy, France). *Haematologica* **96**, 55-61.

139. Mc Laughlin J (2012) An historical overview of radon and its progeny: applications and health effects. *Radiat Prot Dosimetry* **152**, 2-8.

140. McHale CM, Zhang L, Smith MT (2012) Current understanding of the mechanism of benzene-induced leukemia in humans: implications for risk assessment. *Carcinogenesis* **33**, 240-252.

141. McKeown SR, Hatfield P, Prestwich RJ *et al.* (2015) Radiotherapy for benign disease; assessing the risk of radiation-induced cancer following exposure to intermediate dose radiation. *Br J Radiol* **88**, 20150405.

142. McNally RJ, Roman E, Cartwright RA (1999) Leukemias and lymphomas: time trends in the UK, 1984-93. *Cancer Causes Control* **10**, 35-42.

143. McQuilten ZK, Wood EM, Polizzotto MN *et al.* (2014) Underestimation of myelodysplastic syndrome incidence by cancer registries: Results from a population-based data linkage study. *Cancer* **120**, 1686-1694.

144. Measurements NCoRPa (2011) *Second primary cancers and cardiovascular disease after radiation therapy*. no. 170. NCRP.

145. Measurements. NCoRPa (2009) *Ionizing radiation exposure of the population of the United States*. no. 160. Bethesda, MD: NCRP.

146. Medicine Io (2000) *The Five Series Study: Mortality of Military Participants in U.S. Nuclear Weapons Tests.* Washington, DC: The National Academies Press.

147. Mele A, Visani G, Pulsoni A *et al.* (1996) Risk factors for essential thrombocythemia: A case-control study. Italian Leukemia Study Group. *Cancer* **77**, 2157-2161.

148. Melo JV, Barnes DJ (2007) Chronic myeloid leukaemia as a model of disease evolution in human cancer. *Nat Rev Cancer* **7**, 441-453.

149. Mesa RA, Li CY, Ketterling RP *et al.* (2005) Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. *Blood* **105**, 973-977.

150. Mesa RA, Loegering D, Powell HL *et al.* (2005) Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine. *Blood* **106**, 318-327.

151. Metayer C, Curtis RE, Vose J *et al.* (2003) Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study. *Blood* **101**, 2015-2023.

152. Meyer SC, Levine RL (2014) Translational implications of somatic genomics in acute myeloid leukaemia. *Lancet Oncol* **15**, e382-394.

153. Morton LM, Dores GM, Tucker MA *et al.* (2013) Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008. *Blood* **121**, 2996-3004.

154. Morton LM, Wang SS, Devesa SS *et al.* (2006) Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. *Blood* **107**, 265-276.

155. Muirhead CR, Bingham D, Haylock RG *et al.* (2003) Follow up of mortality and incidence of cancer 1952-98 in men from the UK who participated in the UK's atmospheric nuclear weapon tests and experimental programmes. *Occup Environ Med* **60**, 165-172.

156. Muirhead CR, O'Hagan JA, Haylock RG *et al.* (2009) Mortality and cancer incidence following occupational radiation exposure: third analysis of the National Registry for Radiation Workers. *Br J Cancer* **100**, 206-212.

157. Musselman JR, Blair CK, Cerhan JR *et al.* (2013) Risk of adult acute and chronic myeloid leukemia with cigarette smoking and cessation. *Cancer Epidemiol* **37**, 410-416.

158. Nardi V, Winkfield KM, Ok CY *et al.* (2012) Acute myeloid leukemia and myelodysplastic syndromes after radiation therapy are similar to de novo disease and differ from other therapy-related myeloid neoplasms. *J Clin Oncol* **30**, 2340-2347.

159. Network TCGAR (2013) Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. *N Engl J Med* **368**, 2059-2074.

160. Nitiss JL (2009) Targeting DNA topoisomerase II in cancer chemotherapy. *Nat Rev Cancer* **9**, 338-350.

161. Ortmann CA, Kent DG, Nangalia J *et al.* (2015) Effect of mutation order on myeloproliferative neoplasms. *N Engl J Med* **372**, 601-612.

162. Park JH, Qiao B, Panageas KS *et al.* (2011) Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. *Blood* **118**, 1248-1254.

163. Passamonti F, Cervantes F, Vannucchi AM *et al.* (2010) A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). *Blood* **115**, 1703-1708.

164. Passamonti F, Rumi E, Arcaini L *et al.* (2008) Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. *Haematologica* **93**, 1645-1651.

165. Passamonti F, Rumi E, Pungolino E *et al.* (2004) Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. *Am J Med* **117**, 755-761.

166. Patel JP, Gonen M, Figueroa ME *et al.* (2012) Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. *N Engl J Med* **366**, 1079-1089.

167. Pedersen-Bjergaard J, Andersen MK, Christiansen DH (2000) Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation. *Blood* **95**, 3273-3279.

168. Pedersen-Bjergaard J, Christiansen DH, Desta F *et al.* (2006) Alternative genetic pathways and cooperating genetic abnormalities in the pathogenesis of therapy-related myelodysplasia and acute myeloid leukemia. *Leukemia* **20**, 1943-1949.

169. Pesatori AC, Consonni D, Tironi A *et al.* (1993) Cancer in a young population in a dioxin-contaminated area. *Int J Epidemiol* **22**, 1010-1013.

170. Peters S, Glass DC, Milne E *et al.* (2014) Rule-based exposure assessment versus case-by-case expert assessment using the same information in a community-based study. *Occup Environ Med* **71**, 215-219.

171. Pogoda JM, Katz J, McKean-Cowdin R *et al.* (2005) Prescription drug use and risk of acute myeloid leukemia by French-American-British subtype: results from a Los Angeles County case-control study. *Int J Cancer* **114**, 634-638.

172. Pogoda JM, Nichols PW, Ross RK *et al.* (2011) Diagnostic radiography and adult acute myeloid leukaemia: an interview and medical chart review study. *Br J Cancer* **104**, 1482-1486.

173. Polednak AP (2011) US death rates from myeloproliferative neoplasms, and implications for cancer surveillance. *Journal of registry management* **38**, 87-92.

174. Polednak AP (2013) Trend (1999-2009) in U.S. death rates from myelodysplastic syndromes: utility of multiple causes of death in surveillance. *Cancer Epidemiol* **37**, 569-574.

175. Polychronakis I, Dounias G, Makropoulos V *et al.* (2013) Work-related leukemia: a systematic review. *J Occup Med Toxicol* **8**, 14.

176. Poynter JN, Fonstad R, Blair CK *et al.* (2013) Exogenous hormone use, reproductive history and risk of adult myeloid leukaemia. *Br J Cancer* **109**, 1895-1898.

177. Preston-Martin S, Pogoda JM (2003) Estimation of radiographic doses in a case-control study of acute myelogenous leukemia. *Health Phys* **84**, 245-259.

178. Preston-Martin S, Thomas DC, Yu MC *et al.* (1989) Diagnostic radiography as a risk factor for chronic myeloid and monocytic leukaemia (CML). *Br J Cancer* **59**, 639-644.

179. Purdue MP, Hoppin JA, Blair A *et al.* (2007) Occupational exposure to organochlorine insecticides and cancer incidence in the Agricultural Health Study. *Int J Cancer* **120**, 642-649.

180. Raaschou-Nielsen O, Ketzel M, Harbo Poulsen A *et al.* (2016) Traffic-related air pollution and risk for leukaemia of an adult population. *Int J Cancer* **138**, 1111-1117.

181. Rauscher GH, Shore D, Sandler DP (2004) Hair dye use and risk of adult acute leukemia. *Am J Epidemiol* **160**, 19-25.

182. Richardson D, Sugiyama H, Nishi N *et al.* (2009) Ionizing radiation and leukemia mortality among Japanese Atomic Bomb Survivors, 1950-2000. *Radiat Res* **172**, 368-382.

183. Richardson DB, Terschuren C, Pohlabeln H *et al.* (2008) Temporal patterns of association between cigarette smoking and leukemia risk. *Cancer Causes Control* **19**, 43-50.

184. Rinsky RA, Hornung RW, Silver SR *et al.* (2002) Benzene exposure and hematopoietic mortality: A long-term epidemiologic risk assessment. *Am J Ind Med* **42**, 474-480.

185. Risks) SSCoEaNIH (2015) *Potential health effects of exposure to electromagnetic fields (EMF)*.

186. Rivina L, Davoren M, Schiestl RH (2014) Radiation-induced myeloid leukemia in murine models. *Hum Genomics* **8**, 13.

187. Rollig C, Bornhauser M, Thiede C *et al.* (2011) Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: evaluation of the proposed reporting system. *J Clin Oncol* **29**, 2758-2765.

188. Rollison DE, Howlader N, Smith MT *et al.* (2008) Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. *Blood* **112**, 45-52.

189. Ross JA, Blair CK, Cerhan JR *et al.* (2011) Nonsteroidal anti-inflammatory drug and acetaminophen use and risk of adult myeloid leukemia. *Cancer Epidemiol Biomarkers Prev* **20**, 1741-1750.

190. Ruhl JL, Zumar W (2013) ICD-10 essential for healthcare registries. *J AHIMA* **84**, 64-66.

191. Rushton L, Schnatter AR, Tang G *et al.* (2014) Acute myeloid and chronic lymphoid leukaemias and exposure to low-level benzene among petroleum workers. *Br J Cancer* **110**, 783-787.

192. Sakata R, Kleinerman RA, Mabuchi K *et al.* (2012) Cancer mortality following radiotherapy for benign gynecologic disorders. *Radiat Res* **178**, 266-279.

193. Sant M, Allemani C, Tereanu C *et al.* (2010) Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. *Blood* **116**, 3724-3734.

194. Sant M, Minicozzi P, Mounier M *et al.* (2014) Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study. *Lancet Oncol* **15**, 931-942.

195. Saso R, Kulkarni S, Mitchell P *et al.* (2000) Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma. *Br J Cancer* **83**, 91-94.

196. Schlenk RF, Dohner K, Krauter J *et al.* (2008) Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. *N Engl J Med* **358**, 1909-1918.

197. Schnatter AR, Glass DC, Tang G *et al.* (2012) Myelodysplastic syndrome and benzene exposure among petroleum workers: an international pooled analysis. *J Natl Cancer Inst* **104**, 1724-1737.

198. Schwilk E, Zhang L, Smith MT *et al.* (2010) Formaldehyde and leukemia: an updated meta-analysis and evaluation of bias. *J Occup Environ Med* **52**, 878-886.

199. Severson RK, Davis S, Thomas DB *et al.* (1989) Acute myelocytic leukemia and prior allergies. *J Clin Epidemiol* **42**, 995-1001.

200. Severson RK, Stevens RG, Kaune WT *et al.* (1988) Acute nonlymphocytic leukemia and residential exposure to power frequency magnetic fields. *Am J Epidemiol* **128**, 10-20.

201. Shiels MS, Engels EA (2012) Increased risk of histologically defined cancer subtypes in human immunodeficiency virus-infected individuals: clues for possible immunosuppression-related or infectious etiology. *Cancer* **118**, 4869-4876.

202. Shilnikova NS, Preston DL, Ron E *et al.* (2003) Cancer mortality risk among workers at the Mayak nuclear complex. *Radiat Res* **159**, 787-798.

203. Shimizu Y, Pierce DA, Preston DL *et al.* (1999) Studies of the mortality of atomic bomb survivors. Report 12, part II. Noncancer mortality: 1950-1990. *Radiat Res* **152**, 374-389.

204. Shizuru JA, Negrin RS, Weissman IL (2005) Hematopoietic stem and progenitor cells: clinical and preclinical regeneration of the hematolymphoid system. *Annual review of medicine* **56**, 509-538.

205. Shlush LI, Minden MD (2015) Preleukemia: the normal side of cancer. *Current opinion in hematology* **22**, 77-84.

206. Shore RE, Moseson M, Harley N *et al.* (2003) Tumors and other diseases following childhood x-ray treatment for ringworm of the scalp (Tinea capitis). *Health Phys* **85**, 404-408.

207. Shu XO, Gao YT, Linet MS *et al.* (1987) Chloramphenicol use and childhood leukaemia in Shanghai. *Lancet* **2**, 934-937.

208. Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. *CA Cancer J Clin* **66**, 7-30.

209. Sielken RL, Jr., Valdez-Flores C (2015) A comprehensive review of occupational and general population cancer risk: 1,3-Butadiene exposure-response modeling for all leukemia, acute myelogenous leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, myeloid neoplasm and lymphoid neoplasm. *Chem Biol Interact* **241**, 50-58.

210. Simon SL, Preston DL, Linet MS *et al.* (2014) Radiation organ doses received in a nationwide cohort of U.S. radiologic technologists: methods and findings. *Radiat Res* **182**, 507-528.

211. Sinner PJ, Cerhan JR, Folsom AR *et al.* (2005) Positive association of farm or rural residence with acute myeloid leukemia incidence in a cohort of older women. *Cancer Epidemiol Biomarkers Prev* **14**, 2446-2448.

212. Smith A, Howell D, Patmore R *et al.* (2011) Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. *Br J Cancer* **105**, 1684-1692.

213. Smith A, Roman E, Howell D *et al.* (2009) The Haematological Malignancy Research Network (HMRN): a new information strategy for population based epidemiology and health service research. *British journal of haematology* **148**, 739-753.

214. Smith AG, Dovey GJ, Cartwright RA (2000) Topical chloramphenicol and the risk of acute leukaemia in adults. *Pharmacoepidemiol Drug Saf* **9**, 215-219.

215. Sokal JE, Cox EB, Baccarani M *et al.* (1984) Prognostic discrimination in "good-risk" chronic granulocytic leukemia. *Blood* **63**, 789-799.

216. Stebbings JH (1998) Dose-response analyses of osteonecrosis in New Jersey radium workers point to roles for other alpha emitters. *Health Phys* **74**, 602-607.

217. Stevens W, Thomas DC, Lyon JL *et al.* (1990) Leukemia in Utah and radioactive fallout from the Nevada test site. A case-control study. *JAMA* **264**, 585-591.

218. Storm HH, Jorgensen HO, Kejs AM *et al.* (2006) Depleted uranium and cancer in Danish Balkan veterans deployed 1992-2001. *Eur J Cancer* **42**, 2355-2358.

219. Strom SS, Yamamura Y, Kantarijian HM *et al.* (2009) Obesity, weight gain, and risk of chronic myeloid leukemia. *Cancer Epidemiol Biomarkers Prev* **18**, 1501-1506.

220. Swerdlow SH, Campo E, Harris NL *et al.* (editors) (2008) *WHO classification of tumours of haematopoietic and lymphoid tissues*, 4 ed*.* Lyon: International Agency for Research on Cancer.

221. Talbott EO, Xu X, Youk AO *et al.* (2011) Risk of leukemia as a result of community exposure to gasoline vapors: a follow-up study. *Environ Res* **111**, 597-602.

222. Tefferi A, Pardanani A (2015) Myeloproliferative Neoplasms: A Contemporary Review. *JAMA oncology* **1**, 97-105.

223. Tenen DG (2003) Disruption of differentiation in human cancer: AML shows the way. *Nat Rev Cancer* **3**, 89-101.

224. Thariat J, Marcy PY, Lacout A *et al.* (2012) Radiotherapy and radiology: joint efforts for modern radiation planning and practice. *Diagn Interv Imaging* **93**, 342-350.

225. Thygesen LC, Nielsen OJ, Johansen C (2009) Trends in adult leukemia incidence and survival in Denmark, 1943-2003. *Cancer Causes Control* **20**, 1671-1680.

226. Till JE, Beck HL, Aanenson JW *et al.* (2014) Military participants at U.S. Atmospheric nuclear weapons testing--methodology for estimating dose and uncertainty. *Radiat Res* **181**, 471-484.

227. Tomasek L, Darby SC, Swerdlow AJ *et al.* (1993) Radon exposure and cancers other than lung cancer among uranium miners in West Bohemia. *Lancet* **341**, 919-923.

228. Tong H, Hu C, Yin X *et al.* (2013) A Meta-Analysis of the Relationship between Cigarette Smoking and Incidence of Myelodysplastic Syndromes. *PLoS One* **8**, e67537.

229. Traversa G, Menniti-Ippolito F, Da Cas R *et al.* (1998) Drug use and acute leukemia. *Pharmacoepidemiol Drug Saf* **7**, 113-123.

230. Travis LB, Hauptmann M, Gaul LK *et al.* (2003) Site-specific cancer incidence and mortality after cerebral angiography with radioactive thorotrast. *Radiat Res* **160**, 691-706.

231. Travis LB, Holowaty EJ, Bergfeldt K *et al.* (1999) Risk of leukemia after platinum-based chemotherapy for ovarian cancer. *N Engl J Med* **340**, 351-357.

232. Tucker JD (2010) Chromosome translocations and assessing human exposure to adverse environmental agents. *Environ Mol Mutagen* **51**, 815-824.

233. Tynes T, Haldorsen T (2003) Residential and occupational exposure to 50 Hz magnetic fields and hematological cancers in Norway. *Cancer Causes Control* **14**, 715-720.

234. Vardiman J (2012) The classification of MDS: from FAB to WHO and beyond. *Leuk Res* **36**, 1453-1458.

235. Vardiman JW, Harris NL, Brunning RD (2002) The World Health Organization (WHO) classification of the myeloid neoplasms. *Blood* **100**, 2292-2302.

236. Vardiman JW, Thiele J, Arber DA *et al.* (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. *Blood* **114**, 937-951.

237. Verkasalo PK, Pukkala E, Kaprio J *et al.* (1996) Magnetic fields of high voltage power lines and risk of cancer in Finnish adults: nationwide cohort study. *BMJ* **313**, 1047-1051.

238. Vlaanderen J, Lan Q, Kromhout H *et al.* (2012) Occupational benzene exposure and the risk of chronic myeloid leukemia: a meta-analysis of cohort studies incorporating study quality dimensions. *Am J Ind Med* **55**, 779-785.

239. Voso MT, Fenu S, Latagliata R *et al.* (2013) Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database. *J Clin Oncol* **31**, 2671-2677.

240. Wakeford R (2009) Radiation in the workplace-a review of studies of the risks of occupational exposure to ionising radiation. *J Radiol Prot* **29**, A61-79.

241. Wakeford R (2009) More on the risk of cancer among nuclear workers. *J Radiol Prot* **29**, 1-4.

242. Wang P, Liu H, Jiang T *et al.* (2015) Cigarette Smoking and the Risk of Adult Myeloid Disease: A Meta-Analysis. *PLoS One* **10**, e0137300.

243. Wei L, Sugahara T (2000) An introductory overview of the epidemiological study on the population at the high background radiation areas in Yangjiang, China. *J Radiat Res* **41 Suppl**, 1-7.

244. Weiss HA, Darby SC, Fearn T *et al.* (1995) Leukemia mortality after X-ray treatment for ankylosing spondylitis. *Radiat Res* **142**, 1-11.

245. Weiss JR, Baker JA, Baer MR *et al.* (2006) Opposing effects of aspirin and acetaminophen use on risk of adult acute leukemia. *Leuk Res* **30**, 164-169.

246. Wheatley K, Brookes CL, Howman AJ *et al.* (2009) Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials. *British journal of haematology* **145**, 598-605.

247. Wick RR, Nekolla EA, Gaubitz M *et al.* (2008) Increased risk of myeloid leukaemia in patients with ankylosing spondylitis following treatment with radium-224. *Rheumatology (Oxford)* **47**, 855-859.

248. Wilkinson P, Thakrar B, Walls P *et al.* (1999) Lymphohaematopoietic malignancy around all industrial complexes that include major oil refineries in Great Britain. *Occup Environ Med* **56**, 577-580.

249. Williams RR, Horm JW (1977) Association of cancer sites with tobacco and alcohol consumption and socioeconomic status of patients: interview study from the Third National Cancer Survey. *J Natl Cancer Inst* **58**, 525-547.

250. Wong O, Harris F, Yiying W *et al.* (2009) A hospital-based case-control study of acute myeloid leukemia in Shanghai: analysis of personal characteristics, lifestyle and environmental risk factors by subtypes of the WHO classification. *Regul Toxicol Pharmacol* **55**, 340-352.

251. Wright JD, St Clair CM, Deutsch I *et al.* (2010) Pelvic radiotherapy and the risk of secondary leukemia and multiple myeloma. *Cancer* **116**, 2486-2492.

252. Yamamura Y, Oum R, Gbito KY *et al.* (2013) Dietary intake of vegetables, fruits, and meats/beans as potential risk factors of acute myeloid leukemia: a Texas case-control study. *Nutr Cancer* **65**, 1132-1140.

253. Yenson PR, Forrest D, Schmiegelow K *et al.* (2008) Azathioprine-associated acute myeloid leukemia in a patient with Crohn's disease and thiopurine S-methyltransferase deficiency. *Am J Hematol* **83**, 80-83.

254. Yoshinaga S, Hauptmann M, Sigurdson AJ *et al.* (2005) Nonmelanoma skin cancer in relation to ionizing radiation exposure among U.S. radiologic technologists. *Int J Cancer* **115**, 828-834.

255. Yoshinaga S, Mabuchi K, Sigurdson AJ *et al.* (2004) Cancer risks among radiologists and radiologic technologists: review of epidemiologic studies. *Radiology* **233**, 313-321.

256. Zablotska LB, Bazyka D, Lubin JH *et al.* (2013) Radiation and the risk of chronic lymphocytic and other leukemias among chornobyl cleanup workers. *Environ Health Perspect* **121**, 59-65.

257. Zablotska LB, Lane RS, Frost SE *et al.* (2014) Leukemia, lymphoma and multiple myeloma mortality (1950-1999) and incidence (1969-1999) in the Eldorado uranium workers cohort. *Environ Res* **130**, 43-50.

258. Zeichner SB, Arellano ML (2015) Secondary Adult Acute Myeloid Leukemia: a Review of Our Evolving Understanding of a Complex Disease Process. *Curr Treat Options Oncol* **16**, 37.

259. Zhang L, Tang X, Rothman N *et al.* (2010) Occupational exposure to formaldehyde, hematotoxicity, and leukemia-specific chromosome changes in cultured myeloid progenitor cells. *Cancer Epidemiol Biomarkers Prev* **19**, 80-88.

260. Zheng W, Linet MS, Shu XO *et al.* (1993) Prior medical conditions and the risk of adult leukemia in Shanghai, People's Republic of China. *Cancer Causes Control* **4**, 361-368.